ArticleeLife2024
Enhancing CRISPR prime editing by reducing misfolded pegRNA interactions.
Abstract read
In one paragraph
Article in eLife, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Dense RNA motif modifications enable robust in vivo prime editing and enhance efficiencies of diverse editing systems.Nature biomedical engineering · 2026Article
- Advances in prime editing: Molecular innovations, Large-fragment engineering, and AI-driven design.Biodesign research · 2026Review
- Compound delivery of eVLPs enhances prime editing for targeted genome engineering and high-throughput screening.Cell genomics · 2026Article
- Optimised genome editing for precise DNA insertion and substitution using prime editors in zebrafish.eLife · 2026Article
- Overcoming the challenges of genome-editing essential genes.STAR protocols · 2026Review
- Efficient prime editing in vivo and in vitro using lipid nanoparticles.Nature nanotechnology · 2026Article
- Prime Editing, CRISPR-Cas9, and NanoCas Genome Editing for Cancer Treatment.Molecular biotechnology · 2026Review
- Disrupting pegRNA intramolecular complementarity via PBS and spacer sequence alterations can enhance prime editing efficiency.Nucleic acids research · 2026Article
- Efficient genome editing with chimeric oligonucleotide-directed editing.Nature communications · 2026Article
- Gene-sized editing for the therapy of genetic diseases.Functional & integrative genomics · 2026Review
- Enhancement of prime editing by recruiting engineered or evolved components and implementing novel strategies.Biochemistry and biophysics reports · 2026Review
- Anti-mycotoxin additive mixture in cattle feed contaminated with multiple mycotoxins: impacts on performance and health.Tropical animal health and production · 2026Article
- The emerging impact of CRISPR and gene editing on global crop improvement.Transgenic research · 2026Review
- CRISPR/Cas9 in cancer therapy: clinical translation, mechanistic strategies, and therapeutic directions.Frontiers in oncology · 2026Review
- Next-generation T cell immunotherapies engineered with CRISPR base and prime editing: challenges and opportunities.Nature reviews. Clinical oncology · 2025Review
- Base and Prime Editing for Inherited Retinal Diseases: Delivery Platforms, Safety, Efficacy, and Translational Perspectives.Pharmaceutics · 2025Review
- Engineering adeno-associated viral vectors for CRISPR/Cas based in vivo therapeutic genome editing.Biomaterials · 2025Review
- Precise correction of G6PD Viangchan mutation in iPSCs by prime editing strategy.Scientific reports · 2025Article
- Optimized Ribonucleoprotein Complexes Enhance Prime Editing Efficiency in Zebrafish.Animals : an open access journal from MDPI · 2025Article
- An enhanced Eco1 retron editor enables precision genome engineering in human cells without double-strand breaks.Nucleic acids research · 2025Article
Corrections and comments
- Update of
Authors and funding
7 authors.
Weiting ZhangCardiovascular Research Center, Massachusetts General Hospital, Charlestown, United States.
Karl PetriMolecular Pathology Unit and Center for Cancer Research, Massachusetts General Hospital, Charlestown, United States.
Junyan MaCardiovascular Research Center, Massachusetts General Hospital, Charlestown, United States.
Hyunho LeeMolecular Pathology Unit and Center for Cancer Research, Massachusetts General Hospital, Charlestown, United States.
Chia-Lun TsaiCenter for Computational and Integrative Biology, Massachusetts General Hospital, Boston, United States.
J Keith JoungMolecular Pathology Unit and Center for Cancer Research, Massachusetts General Hospital, Charlestown, United States.
Jing-Ruey Joanna YehCardiovascular Research Center, Massachusetts General Hospital, Charlestown, United States.ORCID https://orcid.org/0000-0002-7768-4901
Funding
Center for Genomic Editing and Recording: Development and Application of Next-Generation Genome and Epigenome Editing Methods to Advance the Study and Treatment of Human DiseaseRM1HG009490 · NHGRI · WHITEHEAD INSTITUTE FOR BIOMEDICAL RES · PI Brittany S. Adamson, Martin Joseph Ankrah Aryee · 2017 to 2026
$22.7MADVANCING GENE-EDITING NUCLEASES FOR DIVERSE ZEBRAFISH APPLICATIONSR01GM134069 · NIGMS · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI RANDALL T PETERSON · 2019 to 2026
$3.7MChina Scholarship Council 201808210354Deutsche Forschungsgemeinschaft 417577129Massachusetts General Hospital Hassenfeld Scholar AwardNHGRI NIH HHS RM1 HG009490NIGMS NIH HHS R01 GM134069NIH HHS GM134069NIH HHS HG009490
Abstract
CRISPR prime editing (
Indexed as
CRISPR-Cas SystemsGene EditingRNA, Guide, CRISPR-Cas SystemsZebrafishAnimalsCRISPR-Associated Protein 9Embryo, NonmammalianRNA FoldingCRISPR-Associated Protein 9RNA, Guide, CRISPR-Cas Systemsgene editinggeneticsgenomicsprotein deliveryRNA structurezebrafish
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.